Effectiveness of treatment for localized prostate cancer assessed in Norway

02

Oct 2019

In August 2019, the Norwegian Institute of Public Health (NIPH) has released a health technology assessment report regarding the effectiveness of treatment for localized prostate cancer. This assessment was initially commissioned to NIPH by the Centre for joint decision-making (Samvalgssenteret), which provides patients with relevant and reliable information about a diagnosis and available treatment options. The main objective of the report was to summarize the findings regarding the effectiveness of relevant treatment for localized prostate cancer.

The following results were obtained by NIPH:

  • The effectiveness of the comparison of the following methods is unknown due to the lack of studies:
    • Radical prostatectomy compared to observation;
    • Low-dose-rate brachytherapy compared to observation;
    • Watchful waiting compared to low-dose-rate brachytherapy;
    • Watchful waiting compared to observation;
  • Radical prostatectomy probably improves survival at 10-12 years as compared with watchful waiting, but it is uncertain if the difference is maintained at even longer-term follow-up
  • There is little or no difference in survival after radical prostatectomy compared to low-dose-rate brachytherapy;
  • There is little or no difference in five-year cancer-free survival when comparing surgery with adjuvant radiotherapy with surgery alone, but adjuvant radiotherapy may improve ten-year survival.

See the full health technology assessment report in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more